DE69838338D1 - Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen - Google Patents

Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen

Info

Publication number
DE69838338D1
DE69838338D1 DE69838338T DE69838338T DE69838338D1 DE 69838338 D1 DE69838338 D1 DE 69838338D1 DE 69838338 T DE69838338 T DE 69838338T DE 69838338 T DE69838338 T DE 69838338T DE 69838338 D1 DE69838338 D1 DE 69838338D1
Authority
DE
Germany
Prior art keywords
antimykotica
mushroom
induced tissue
skin injection
tissue skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69838338T
Other languages
English (en)
Other versions
DE69838338T2 (de
Inventor
Jens Ponikau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69838338D1 publication Critical patent/DE69838338D1/de
Publication of DE69838338T2 publication Critical patent/DE69838338T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
DE69838338T 1997-10-22 1998-10-22 Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen Expired - Lifetime DE69838338T2 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US6270997P 1997-10-22 1997-10-22
US62709P 1997-10-22
US6341897P 1997-10-28 1997-10-28
US6341497P 1997-10-28 1997-10-28
US63414P 1997-10-28
US63418P 1997-10-28
US8327298P 1998-04-28 1998-04-28
US83272P 1998-04-28
US8639798P 1998-05-22 1998-05-22
US86397P 1998-05-22
PCT/US1998/022403 WO1999020261A2 (en) 1997-10-22 1998-10-22 Use of antigunal agents for the topial treatment of fungus-induced mucositis

Publications (2)

Publication Number Publication Date
DE69838338D1 true DE69838338D1 (de) 2007-10-11
DE69838338T2 DE69838338T2 (de) 2008-05-21

Family

ID=27535591

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69838338T Expired - Lifetime DE69838338T2 (de) 1997-10-22 1998-10-22 Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen

Country Status (28)

Country Link
US (9) US6291500B2 (de)
EP (2) EP1024814B1 (de)
JP (3) JP2001520188A (de)
KR (4) KR20010031363A (de)
CN (1) CN1143679C (de)
AP (1) AP2000001805A0 (de)
AT (1) ATE371457T1 (de)
AU (1) AU1195999A (de)
BG (1) BG104371A (de)
BR (1) BR9814615A (de)
CA (1) CA2308201C (de)
DE (1) DE69838338T2 (de)
DK (1) DK1024814T3 (de)
EA (1) EA200000439A1 (de)
EE (1) EE200000253A (de)
ES (1) ES2292210T3 (de)
HK (1) HK1029935A1 (de)
HU (1) HUP0004170A3 (de)
ID (1) ID26104A (de)
IL (2) IL135774A0 (de)
IS (1) IS5463A (de)
NO (1) NO325714B1 (de)
OA (1) OA11351A (de)
PL (1) PL340606A1 (de)
PT (1) PT1024814E (de)
SK (1) SK5732000A3 (de)
TR (1) TR200001117T2 (de)
WO (1) WO1999020261A2 (de)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045815A (en) * 1997-08-15 2000-04-04 Board Of Regents, The University Of Texas System Parenteral pimaricin as treatment of systemic infections
US6844004B2 (en) 1997-08-15 2005-01-18 Board Of Regents, The University Of Texas System Topical formulations of natamycin/pimaricin
PL340606A1 (en) * 1997-10-22 2001-02-12 Jens Ponikau Methods of and materials for treating and preventing mucositis
GB9826656D0 (en) 1998-12-03 1999-01-27 Novartis Ag Organic compounds
AU5975700A (en) * 1999-07-02 2001-01-22 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
SE521431C2 (sv) * 1999-12-02 2003-11-04 Sca Hygiene Prod Ab Användning av en pH-buffrande substans för att förhindra hudinfektioner orsakade av Candida Albicans
AU2001232787A1 (en) * 2000-01-14 2001-07-24 University Of Virginia Patent Foundation Airway alkalinization as therapy for airway diseases
AU2001236448A1 (en) * 2000-02-18 2001-08-27 Eli Lilly And Company Methods of treatment for non-invasive fungus-induced mucositis with cyclohexapeptide antifungal agents
US7150888B1 (en) 2000-04-03 2006-12-19 Inhalation, Inc. Methods and apparatus to prevent colds, influenzaes, tuberculosis and opportunistic infections of the human respiratory system
US7048953B2 (en) * 2000-04-03 2006-05-23 Inhalation, Inc. Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)
US8404217B2 (en) * 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6767537B2 (en) 2000-05-26 2004-07-27 Phil Arnold Nicolay Composition and method for the treatment of sinusitis
AU2001282988B2 (en) * 2000-07-26 2006-01-05 Atopic Pty Ltd Methods for treating atopic disorders
DE50111407D1 (de) * 2000-09-14 2006-12-21 Waldemar Gottardi Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
WO2002041837A2 (en) * 2000-11-22 2002-05-30 Rxkinetix, Inc. Treatment of mucositis
CA2432319A1 (en) 2000-12-21 2002-07-18 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US7770577B2 (en) * 2001-05-15 2010-08-10 Gregory E Conner Methods and devices for treating lung dysfunction
WO2002098463A1 (fr) * 2001-06-05 2002-12-12 The New Industry Research Organization Compositions antifongiques
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
US20040019316A1 (en) * 2002-03-13 2004-01-29 Morris John K. Nasal airway delivery, decongestion system (NADDS)
US20060148770A1 (en) * 2002-06-10 2006-07-06 Jason Fong Combinations for the treatment of rheumatoid arithritis
PL373033A1 (en) * 2002-06-20 2005-08-08 Novartis Consumer Health S.A. Nasal compositions comprising a mucopolysaccharide and propylene glycol
US20050032896A1 (en) * 2002-06-21 2005-02-10 Liisa Neumann Use of synthetic retinoic acid in form of 13-cis vitamin A for treatment of autism
JP2005538067A (ja) * 2002-07-02 2005-12-15 ノバルティス アクチエンゲゼルシャフト 副鼻腔炎の処置方法
US20040029893A1 (en) * 2002-07-23 2004-02-12 Lane Edward M. Method of treatment of non-invasive mucositis
ES2428354T3 (es) 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
MXPA05004580A (es) * 2002-10-29 2005-07-26 Transave Inc Liberacion sostenida de anti - infecciosos.
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
WO2005000195A2 (en) * 2002-11-13 2005-01-06 Rosenberg Yvonne J A pretreatment or post exposure treatment for exposure to a toxic substance by pulmonary delivery (inhaler) of a bioscavenger
US6890323B1 (en) * 2002-12-03 2005-05-10 University Of Florida Small volume effusion trap
TW200503781A (en) * 2002-12-31 2005-02-01 Nektar Therapeutics Aerosolizable pharmaceutical formulation for fungal infection therapy
AU2004222340B2 (en) 2003-03-14 2009-11-12 Intersect Ent, Inc. Sinus delivery of sustained release therapeutics
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US20050159369A1 (en) * 2003-08-20 2005-07-21 Qtm Llc Method of treatment of otitis externa
US20070078116A1 (en) * 2003-08-20 2007-04-05 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US20050043251A1 (en) * 2003-08-20 2005-02-24 Fairfield Clinical Trials, Llc Method of treatment of otitis externa
US7731976B2 (en) * 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
US20060177424A1 (en) * 2003-08-29 2006-08-10 Cobb Mark L Treatment of disease states and adverse physiological conditions utilizing anti-fungal compositions
US7749509B2 (en) * 2003-08-29 2010-07-06 Cobb And Company, Llp Treatment of autism using probiotic composition
US7759105B2 (en) * 2003-08-29 2010-07-20 Cobb & Company, Llp Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US8192733B2 (en) 2003-08-29 2012-06-05 Cobb & Associates Probiotic composition useful for dietary augmentation and/or combating disease states and adverse physiological conditions
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
MXPA06002719A (es) * 2003-09-09 2006-09-04 3M Innovative Properties Co Composiciones antimicrobianas y metodos.
CA2538119C (en) * 2003-09-09 2013-05-14 3M Innovative Properties Company Concentrated antimicrobial compositions and methods
WO2005027851A2 (en) 2003-09-18 2005-03-31 Children's Medical Center Corporation Treatment of severe distal colitis
EP1706128B1 (de) * 2003-12-08 2010-07-21 CPEX Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung
US20070196457A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
US20070196453A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US20080019927A1 (en) * 2004-06-07 2008-01-24 Jie Zhang Compositions and methods for dermally treating neuropathy with minoxidil
US20070190124A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US20070189978A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Compositions and methods for dermally treating musculoskeletal pain
US20070196293A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for treating photo damaged skin
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US20070196325A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for dermally treating infections
US20060009424A1 (en) * 2004-07-06 2006-01-12 Anatoly Kogan Nasaleaze
EP1776109B1 (de) 2004-08-13 2008-12-31 Schering-Plough Ltd. Pharmazeutische formulierungen mit einem antibiotikum, einem triazol und einem kortikosteroid
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use
US8198326B2 (en) * 2004-09-07 2012-06-12 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
US9028852B2 (en) * 2004-09-07 2015-05-12 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
KR100675379B1 (ko) * 2005-01-25 2007-01-29 삼성전자주식회사 프린팅 시스템 및 프린팅 방법
KR20070104931A (ko) 2005-02-09 2007-10-29 마커사이트, 인코포레이티드 안구 치료용 제제
US8476319B2 (en) * 2005-03-10 2013-07-02 3M Innovative Properties Company Methods of treating ear infections
US9826770B2 (en) * 2005-03-10 2017-11-28 3M Innovative Properties Company Antimicrobial compositions comprising esters of hydroxycarboxylic acids
CN101175474B (zh) * 2005-03-10 2011-09-07 3M创新有限公司 降低微生物污染的方法
US20060229364A1 (en) * 2005-03-10 2006-10-12 3M Innovative Properties Company Antiviral compositions and methods of use
WO2006099232A2 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Antimicrobial pet wipes
EP2298319A1 (de) 2005-04-04 2011-03-23 Sinexus, Inc. Vorrichtung und Verfahren zur Behandlung von Erkrankungen der Nasennebenhöhlen
WO2006119292A2 (en) * 2005-04-29 2006-11-09 Henkin, Robert Methods for detection of biological substances
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
WO2007038466A2 (en) * 2005-09-27 2007-04-05 Cobb & Company Treatment of bipolar disorder utilizing anti-fungal compositions
ITRM20050561A1 (it) * 2005-11-10 2007-05-11 D M G Italia S R L Soluzione otologica e metodo per la sua preparazione.
DK1965787T3 (da) * 2005-11-30 2013-06-03 Endo Pharmaceuticals Inc Behandling af xerostomi med en svovlindeholdende antioxidant
US8226975B2 (en) 2005-12-08 2012-07-24 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
WO2007070661A2 (en) * 2005-12-13 2007-06-21 Naryx Pharma, Inc. Methods of measuring symptoms of chronic rhinosinusitis
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
US20070219600A1 (en) * 2006-03-17 2007-09-20 Michael Gertner Devices and methods for targeted nasal phototherapy
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
US20100190735A1 (en) * 2006-03-28 2010-07-29 Myrex Pharmaceuticals Inc. Mouthwash and Method of Using Same for the Treatment of Mucositis or Stomatitis
WO2007117550A2 (en) * 2006-04-06 2007-10-18 Transave, Inc. Methods for coacervation induced liposomal encapsulation and formulations thereof
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
US20070286813A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
US20070286812A1 (en) * 2006-06-09 2007-12-13 Toutounghi Camille Nasal formulation
US8535707B2 (en) 2006-07-10 2013-09-17 Intersect Ent, Inc. Devices and methods for delivering active agents to the osteomeatal complex
WO2008008494A2 (en) * 2006-07-13 2008-01-17 Accentia Biopharmaceuticals, Inc. Methods and compositions for treating mucosal inflammation
US20080075793A1 (en) * 2006-09-21 2008-03-27 Dunshee Wayne K Antiviral compositions and methods of use
WO2008039987A2 (en) * 2006-09-28 2008-04-03 Transave, Inc. Methods of treating pulmonary distress
WO2008063756A2 (en) * 2006-10-03 2008-05-29 Accentia Biopharmaceuticals, Inc. Mucosally non-irritative amphotericin b formulations and methods for treating non-invasive fungus-induced mucositis
EP2091324B1 (de) 2006-10-27 2016-12-28 3M Innovative Properties Company Antimikrobielle zusammensetzungen
US20110146671A1 (en) * 2006-12-01 2011-06-23 James Zhou Liu Pharmaceutical compositions and methods of delivering the same
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
WO2008134721A1 (en) * 2007-04-30 2008-11-06 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
DK2231065T3 (da) 2007-12-18 2021-02-01 Intersect Ent Inc Selvekspanderende anordninger
CN101214221A (zh) * 2007-12-27 2008-07-09 黄明 治疗鼻炎鼻窦炎药物制剂
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
AU2009228163B2 (en) * 2008-03-28 2012-08-30 Glaxosmithkline Llc Methods of treatment
WO2009146104A1 (en) 2008-04-02 2009-12-03 Accentia Biopharmaceuticals, Inc. Formulations, devices and methods for treating and preventing mucositis
KR20210107137A (ko) 2008-04-21 2021-08-31 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
KR101534422B1 (ko) 2008-05-14 2015-07-09 오토노미, 인코포레이티드 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
JP5839189B2 (ja) * 2008-07-21 2016-01-06 オトノミ—，インク． 耳の不調の治療用の制御放出性の抗菌性組成物および方法
US8580801B2 (en) * 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
AU2009276505B2 (en) 2008-08-01 2015-04-23 Intersect Ent, Inc. Methods and devices for crimping self-expanding devices
US10357640B2 (en) 2009-05-15 2019-07-23 Intersect Ent, Inc. Expandable devices and methods for treating a nasal or sinus condition
WO2011100170A1 (en) * 2010-02-10 2011-08-18 Albert Cha Nasal irrigation systems
US20120003300A1 (en) * 2010-06-30 2012-01-05 Pangaea Laboratories Ltd Composition Comprising Vascular Endothelial Growth Factor (VEGF) for the Treatment of Hair Loss
US9669044B2 (en) 2010-12-14 2017-06-06 Utah State University Aminoglycoside and azole compositions and methods
KR102009698B1 (ko) 2011-12-20 2019-08-13 바이옴 테라퓨틱스 리미티드 진균 감염의 치료를 위한 국소 오일 조성물
JP6402097B2 (ja) 2012-05-21 2018-10-10 インスメッド インコーポレイテッド 肺感染症を処置するためのシステム
ES2743039T3 (es) 2012-11-29 2020-02-18 Insmed Inc Formulaciones de vancomicina estabilizada
CN112089505B (zh) 2013-03-14 2024-01-05 因特尔赛克特耳鼻喉公司 用于治疗鼻窦病状的系统、装置以及方法
WO2014186804A2 (en) * 2013-05-17 2014-11-20 Utah State University Aminoglycoside and azole compositions and methods
CN104208701A (zh) * 2013-05-29 2014-12-17 天津金耀集团有限公司 含有抗真菌药物的复方吸入制剂
FR3009622B1 (fr) * 2013-08-09 2015-08-07 Novacyt Procede et dispositif de lavage d'un dispositif de pipetage-distribution
EP3038707A4 (de) 2013-08-27 2017-03-01 Otonomy, Inc. Behandlung von ohrerkrankungen bei kindern
WO2015126944A1 (en) 2014-02-18 2015-08-27 Henkin Robert I Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
SI3142643T1 (sl) 2014-05-15 2019-11-29 Insmed Inc Postopki za zdravljenje pljučnih netuberkuloznih mikobakterijskih infekcij
CA2982660C (en) * 2014-11-21 2023-01-24 F2G Limited 2-(1,5-dimethyl-3-phenyl-1h-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazine-1-yl)phenyl)-2-oxoacetamide and derivatives thereof for use as antifungal agents
US20180071281A1 (en) * 2016-08-19 2018-03-15 Gerbe Labs Inc. Treating chronic rhinosinusitis
EP3512513A4 (de) 2016-09-16 2020-04-15 Otonomy, Inc. Gelformulierungen für das ohr zur behandlung von otitis externa
US11390671B2 (en) 2017-06-06 2022-07-19 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
WO2019183006A1 (en) * 2018-03-19 2019-09-26 Liang Gui Bai Methods and compositions for treating idiopathic pulmonary fibrosis
US11571386B2 (en) 2018-03-30 2023-02-07 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CN111249219B (zh) * 2018-11-30 2023-08-11 中南大学湘雅三医院 治疗耳道真菌的滴耳液及其制备方法
EP3930808A4 (de) * 2019-02-27 2022-12-14 Oticara, Inc. Verfahren zur behandlung von nasaler, sinonasaler und nasopharyngealer gewebeinfektion und/oder -entzündung
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
DE2350315C2 (de) * 1973-10-06 1984-01-12 Johnson & Johnson GmbH, 4000 Düsseldorf Pharmazeutische und kosmetische Präparate zur äußerlichen Anwendung
US4209447A (en) 1975-01-27 1980-06-24 Janssen Pharmaceutica N.V. Imidazole derivatives and intermediates in their preparation
US3991750A (en) 1975-04-28 1976-11-16 Syntex Corporation Dromostanolone propionate implant pellet useful for producing weight gains in animals and suppressing estrus in female animals
US4402957A (en) 1979-04-04 1983-09-06 Janssen Pharmaceutica N.V. Heterocyclic derivatives of [4-(piperazin-1-ylphenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4334538A (en) 1979-12-12 1982-06-15 Juhn Steven K Aspirator for collecting liquid samples
US4432991A (en) 1981-07-13 1984-02-21 American Cyanamid Company Therapeutically active 3-amino-1-phenyl(and substituted phenyl)-2-pyrazolines
US4883785A (en) * 1984-07-27 1989-11-28 Chow Wing Sun Complex of anti-fungal agent and cyclodextrin and method
US4916134A (en) 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US5487739A (en) 1987-11-17 1996-01-30 Brown University Research Foundation Implantable therapy systems and methods
US5075309A (en) 1989-06-09 1991-12-24 Janssen Pharmaceutica N.V. Antifungal 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]triazolones and imidazolones
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5310545A (en) * 1991-04-11 1994-05-10 Drore Eisen Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter
US5248504A (en) 1992-03-02 1993-09-28 Friedman William H Method of treatment for nasal and sinus dysfunction
DE69331387T2 (de) 1992-09-10 2002-08-22 Childrens Medical Center Biodegradierbare polymeren matrizen mit verzoegerter freisetzung von lokalanaesthetika
CA2106034A1 (en) 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
WO1994016710A1 (en) 1993-01-21 1994-08-04 Janssen Pharmaceutica N.V. Topical ketoconazole compositions
RU2128053C1 (ru) 1993-03-19 1999-03-27 Налепо Лидия Филимоновна Средство для лечения бронхиальной астмы (варианты)
PH31594A (en) 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
US5582167A (en) 1994-03-02 1996-12-10 Thomas Jefferson University Methods and apparatus for reducing tracheal infection using subglottic irrigation, drainage and servoregulation of endotracheal tube cuff pressure
US5952314A (en) * 1994-04-01 1999-09-14 Demichele; Stephen Joseph Nutritional product for a person having ulcerative colitis
EP0771205A2 (de) * 1994-06-28 1997-05-07 Dr. Zerle Gmbh Neue klinische anwendungen von polyen-makroliden
US5599795A (en) * 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US5658881A (en) 1994-10-14 1997-08-19 Twk, Inc. Method for topical inhibition of the metabolic activity of cytochrome P450
US5679648A (en) * 1994-11-30 1997-10-21 The University Hospital Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides
US5614206A (en) 1995-03-07 1997-03-25 Wright Medical Technology, Inc. Controlled dissolution pellet containing calcium sulfate
JP3434396B2 (ja) * 1995-06-30 2003-08-04 株式会社日立ユニシアオートモティブ 鼻腔用投薬器
GB9514878D0 (en) 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
DE19541815B4 (de) * 1995-11-09 2008-04-10 Bannert, Christian, Dr. Verwendung einer Lösung von Polyethylenglykol in Wasser als wässrige Spüllösung zur Prävention oder Behandlung von zähem Schleim, der in Verbindung mit Strahlen- oder/und Chemotherapie-induzierten Erkrankungen der Schleimhäute auftritt
US5756127A (en) 1996-10-29 1998-05-26 Wright Medical Technology, Inc. Implantable bioresorbable string of calcium sulfate beads
RU2139707C1 (ru) 1996-12-24 1999-10-20 ОАО Нижегородский химико-фармацевтический завод Суппозитории, обладающие противогрибковым действием (варианты)
PL340606A1 (en) * 1997-10-22 2001-02-12 Jens Ponikau Methods of and materials for treating and preventing mucositis
US5897872A (en) 1997-11-12 1999-04-27 Picciano; Dante J. Iodine-containing nasal moisturizing saline solution
WO1999038459A2 (en) 1998-01-30 1999-08-05 Wilk Patent Development Corporation Transmyocardial coronary artery bypass and revascularization

Also Published As

Publication number Publication date
KR20060002015A (ko) 2006-01-06
US20020052390A1 (en) 2002-05-02
ATE371457T1 (de) 2007-09-15
HUP0004170A3 (en) 2001-12-28
EA200000439A1 (ru) 2000-12-25
US20010002400A1 (en) 2001-05-31
HK1029935A1 (en) 2001-04-20
IL135774A0 (en) 2001-05-20
ID26104A (id) 2000-11-23
PT1024814E (pt) 2007-11-29
CN1143679C (zh) 2004-03-31
US6555566B2 (en) 2003-04-29
HUP0004170A2 (hu) 2001-05-28
DK1024814T3 (da) 2008-01-02
WO1999020261A3 (en) 2000-02-17
NO20002069L (no) 2000-06-21
IL135774A (en) 2006-08-20
US20030153516A1 (en) 2003-08-14
US6291500B2 (en) 2001-09-18
KR20070069220A (ko) 2007-07-02
IS5463A (is) 2000-04-19
AU1195999A (en) 1999-05-10
US20010006944A1 (en) 2001-07-05
KR100883149B1 (ko) 2009-02-10
DE69838338T2 (de) 2008-05-21
NO20002069D0 (no) 2000-04-19
US6207703B1 (en) 2001-03-27
CA2308201A1 (en) 1999-04-29
ES2292210T3 (es) 2008-03-01
CA2308201C (en) 2010-09-28
US20090253645A1 (en) 2009-10-08
JP2007008951A (ja) 2007-01-18
US20030091510A1 (en) 2003-05-15
EP1857113A3 (de) 2007-12-19
TR200001117T2 (tr) 2000-09-21
KR20010031363A (ko) 2001-04-16
SK5732000A3 (en) 2000-10-09
US20010031779A1 (en) 2001-10-18
EP1024814B1 (de) 2007-08-29
WO1999020261A2 (en) 1999-04-29
EP1024814A2 (de) 2000-08-09
OA11351A (en) 2003-12-18
AP2000001805A0 (en) 2000-06-30
JP2006096770A (ja) 2006-04-13
EE200000253A (et) 2001-06-15
PL340606A1 (en) 2001-02-12
US20050124561A1 (en) 2005-06-09
JP2001520188A (ja) 2001-10-30
BR9814615A (pt) 2001-10-16
CN1282251A (zh) 2001-01-31
EP1857113A2 (de) 2007-11-21
KR20060066753A (ko) 2006-06-16
BG104371A (en) 2000-12-29
NO325714B1 (no) 2008-07-07

Similar Documents

Publication Publication Date Title
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE69829921D1 (de) Vorrichtung zur Behandlung von Körpergewebe
DE69827424D1 (de) Vorrichtung zur gesteuerten thermischen Behandlung von Gewebe
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69836640D1 (de) Vorrichtung zur behandlung von gewebe mit mehrfach-elektroden
DE69739303D1 (de) Vorrichtung zur thermischen behandlung von gewebe
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
DE69926385D1 (de) Behandlung von geweben
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE69634519D1 (de) Katheter zur ablation von atrio-ventikulären gewebe
DE60141230D1 (de) Verwendung von Botulinum Toxin zur Behandlung von neuralgischen Schmerzen
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
ATA46794A (de) Einrichtung zur behandlung von hautzonen
DE60025233D1 (de) Verfahren zur beruhigen von menschen unter verwendung von körperpflegemitteln
DE69711311D1 (de) Vorrichtung zur thermischen Behandlung von Gewebe
DE69729817D1 (de) Behandlung von Aldehyd-fixierten Geweben
DE59707519D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE69807466T2 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
PT935692E (pt) Tratamento de tecido com celulase e oxidoredutase
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
ID21874A (id) Penggunaan 1-hidroksi-2-piridon untuk pengobatan infeksi urap kulit
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESE, US

8364 No opposition during term of opposition